Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Reumatismo ; 74(1)2022 May 03.
Article in English | MEDLINE | ID: mdl-35506320

ABSTRACT

The aim of this narrative review is to discuss the results of studies investigating the role of physical activity in knee osteoarthritis (OA). We also formulated two evidence-based exercise programs that could be prescribed to patients with symptomatic knee OA or after joint replacement. The PubMed and Google Scholar databases were searched for articles related to knee OA and physical activity. A total of 86 papers written in English and published from 1957 to 2021 were selected. Adapted physical activity, even at high intensity, does not appear to trigger or exacerbate knee OA; on the contrary, it may prevent obesity or lower limb muscle weakness, both of which are considered predisposing factors for the disease. In patients already diagnosed with knee OA, scientific evidence suggests that both land-based and aquatic activities combining aerobics, strength, and endurance programs are safe and effective. Physical interventions tailored to the patient may also accelerate recovery time after knee arthroplasty. Knee OA is a painful and disabling rheumatic disease that is very common in the elderly population. Pharmacotherapy has a modest effect in controlling disease progression, possibly due to the still limited understanding of OA pathogenesis. Non-pharmacologic interventions, including dietary and lifestyle changes and physical activity, may be more effective and safer than drugs in preventing or treating knee OA.


Subject(s)
Osteoarthritis, Knee , Aged , Disease Progression , Exercise , Exercise Therapy/methods , Humans , Osteoarthritis, Knee/etiology , Osteoarthritis, Knee/prevention & control
2.
Reumatismo ; 71(1): 19-23, 2019 Apr 01.
Article in English | MEDLINE | ID: mdl-30932439

ABSTRACT

Klotho is a transmembrane and soluble glycoprotein that governs vascular integrity. Previous studies have demonstrated reduced serum klotho concentrations in patients with systemic sclerosis (SSc), and it is known that klotho deficiency can impair the healing of digital ulcers related to microvessel damage. The aim of this study was to evaluate the association between serum klotho levels and nailfold capillaroscopic abnormalities in SSc patients. We retrospectively enrolled 54 consecutive patients with SSc diagnosed on the basis of the 2013 EULAR/ACR criteria [11 with diffuse SSc; 47 females; median age 68.0 years (IQ 18); median disease duration 11.0 years (IQ 7)]. Serum klotho concentrations were determined by means of an enzyme-linked immunosorbent assay. On the basis of the 2000 classification of Cutolo et al., 14 patients had normal nailfold capillaroscopic findings, 8 had an early scleroderma pattern, 21 an active scleroderma pattern, and 11 a late scleroderma pattern. The median serum klotho concentration was 0.29 ng/mL (IQ 1). Regression analysis of variation showed an inverse correlation between serum klotho concentrations and the severity of the capillaroscopic pattern (p=0.02; t -2.2284), which was not influenced by concomitant treatment. Logistic regression did not reveal any significant association between the risk of developing digital ulcers and nailfold capillaroscopic patterns, serum klotho levels, or concomitant medications. The presence of avascular areas significantly correlated with calcinosis (p=0.006). In line with previous studies, our findings confirm that klotho plays a role in preventing microvascular damage detected with nailfold capillaroscopy.


Subject(s)
Calcinosis/complications , Glucuronidase/blood , Microscopic Angioscopy , Nail Diseases/blood , Nails/blood supply , Scleroderma, Systemic/blood , Adult , Aged , Antibodies, Antinuclear/blood , Biomarkers/blood , Female , Humans , Klotho Proteins , Male , Middle Aged , Nail Diseases/etiology , Regression Analysis , Retrospective Studies , Ulcer/etiology
3.
Open Rheumatol J ; 12: 125-128, 2018.
Article in English | MEDLINE | ID: mdl-30197706

ABSTRACT

BACKGROUND: Aseptic osteonecrosis of the hip is a clinical entity in which the necrotic process of the bone leads to pain and progressive disability. OBJECTIVE: Pamidronate seems to reduce drastically the activation of the osteoclasts so that it can be useful only in the early stage of the disease, delaying the time of bone collapsing. METHOD: A 27-years-old male was treated with pamidronate for three consecutive days every four weeks. RESULTS: After three months the patient came back at control showing a marked improvement in clinical condition, referred full recover from pain and dysmotility with improvement of the quality of life, which was confirmed by the result of MRI he had for control. CONCLUSION: We reported a case of aseptic osteonecrosis of the hip which was successfully treated pamidronate at dosage of 45 mg.

4.
Reumatismo ; 69(4): 156-163, 2017 Dec 21.
Article in English | MEDLINE | ID: mdl-29320841

ABSTRACT

The aim was to evaluate the role of klotho in the pathogenesis of systemic sclerosis (SSc), through the measurement of its serum concentration in SSc patients compared to healthy controls, and to assess the association with cutaneous and visceral involvement. Blood samples obtained from both SSc patients and healthy controls were analysed by an ELISA assay for the detection of human klotho. SSc patients were globally evaluated for disease activity and assessed through the modified Rodnan's Skin Score, Medsger's scale, pulmonary function tests, 2D-echocardiography, nailfold capillaroscopy and laboratory tests. Our cohort consisted of 69 SSc patients (61 females, mean age 64.5±12.5 years, median disease duration 9.0 (IQR 8) years) and 77 healthy controls (28 females, mean age 49.7±10.2 years). In the group of SSc patients, 19 (27.5%) suffered from a diffuse form of SSc. All patients were receiving IV prostanoids, and some of them were concomitantly treated with immunosuppressive drugs (prednisone, hydroxychloroquine, mofetil mycophenolate, methotrexate, cyclosporin A and azathioprine). The median serum concentration of klotho was significantly lower in patients compared to controls (0.23 ng/mL vs 0.60 ng/mL; p<0.001). However, Spearman's test showed no significant association between klotho serum levels and disease activity, concerning either clinical, laboratory or instrumental findings. Our data show a significant deficit of klotho in SSc patients although any significant association was detected between klotho serum concentration and the clinical, laboratory or instrumental features of the disease. However, due to the limits of the study, further investigations are required.


Subject(s)
Glucuronidase/physiology , Scleroderma, Systemic/blood , Adult , Aged , Biomarkers , Female , Glucuronidase/blood , Humans , Immunosuppressive Agents/therapeutic use , Klotho Proteins , Lung/pathology , Male , Microscopic Angioscopy , Middle Aged , Osteoporosis/etiology , Prostaglandins/therapeutic use , Scleroderma, Systemic/complications , Scleroderma, Systemic/drug therapy , Scleroderma, Systemic/pathology , Statistics, Nonparametric
5.
Reumatismo ; 68(2): 83-9, 2016 Sep 09.
Article in English | MEDLINE | ID: mdl-27608796

ABSTRACT

The aim of this study was to determine the prevalence of T helper 9 (Th9) lymphocytes in rheumatoid arthritis (RA) patients and to identify a possible association between the percentage of Th9 and the discontinuation of a biological treatment with an anti-tumor necrosis factor (TNF) (infliximab). We collected peripheral blood mononuclear cells (PBMCs) from 55 consecutive RA outpatients and 10 healthy controls. Among RA patients, 15 were not receiving any immunosuppressive drug, 20 were successfully treated with infliximab and 20 discontinued infliximab because of adverse events or inefficacy and were treated with other biological agents. PBMCs were cultured with/without infliximab 50 mg/L for 18 h, and the percentage of Th9 cells was assessed by means of flow cytometry. Th9 lymphocytes were identified as interferon gamma, interleukin (IL)4-, IL17-, IL9-secreting cluster of differentiation 4 (CD4)+ T cells. Cytometric analysis revealed no significant decrease in the percentage of Th9 cells after infliximab exposure in any of the groups, although it was lower in healthy controls than RA patients either before and after the infliximab stimulation assay. Th9 cells are IL-9-secreting T helper lymphocytes whose role in RA is still poorly known. IL-9 levels are increased in RA patients, in whom this cytokine plays a crucial role. Th9 cells are the major producers of IL-9, and their prevalence is higher in RA patients than in healthy subjects; however our experiment in vitro does not demonstrate an association between Th9 lymphocytes and the response to infliximab. Further studies are required to evaluate the real involvement of Th9 population in the immunogenicity of anti-TNF agents.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/drug therapy , Infliximab/therapeutic use , Interleukin-9/blood , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/immunology , Biomarkers/blood , Body Mass Index , Case-Control Studies , Female , Humans , In Vitro Techniques , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Male , Middle Aged , Outpatients , Predictive Value of Tests , Sensitivity and Specificity
6.
Reumatismo ; 68(2): 104-8, 2016 Sep 09.
Article in English | MEDLINE | ID: mdl-27608800

ABSTRACT

It is still unknown whether there is an association between the use of certolizumab pegol (CZP) in rheumatic patients and the onset of cardiac arrhythmias. We describe the cases of two patients with rheumatoid arthritis (RA) treated with CZP as the first-line biological drug and methotrexate (MTX), who developed an arrhythmic event. The first was a 60-year-old, hypertensive male smoker, the second a 66-year-old dyslipidemic female non-smoker. Both were diagnosed as having RA in 2010, and started treatment with MTX plus CZP. The first patient developed undatable atrial fibrillation, which was resistant to pharmacological treatment and electrical cardioversion. The second patient developed an atrial flutter, which was treated with a betablocker. In both cases, we set a cautious interval between two consecutive administrations of CZP and, in the first case, also reduced the dose of MTX without any worsening of RA activity. Although many studies have shown that tumor necrosis factor (TNF)-alpha plays a pathogenetic role in inducing an arrhythmogenic substrate that is apparently rescued by anti-TNF drugs, there is still a lack of conclusive data. We suggest caution in any patient developing a cardiac event (including rhythm disorders) during treatment with a conventional or biological disease-modifying anti-rheumatic drug.


Subject(s)
Antirheumatic Agents/adverse effects , Arrhythmias, Cardiac/chemically induced , Certolizumab Pegol/adverse effects , Aged , Antirheumatic Agents/administration & dosage , Arrhythmias, Cardiac/drug therapy , Arthritis, Rheumatoid/drug therapy , Bisoprolol/therapeutic use , Certolizumab Pegol/administration & dosage , Drug Therapy, Combination , Female , Fibrinolytic Agents/therapeutic use , Humans , Hypertension/complications , Male , Middle Aged , Pyrazoles/therapeutic use , Pyridones/therapeutic use , Risk Factors , Smoking/adverse effects , Sympatholytics/therapeutic use , Treatment Outcome
7.
Reumatismo ; 66(1): 44-7, 2014 06 06.
Article in English | MEDLINE | ID: mdl-24938196

ABSTRACT

Chronic pain is a healthcare problem that significantly affects the mental health, and the professional and private life of patients. It can complicate many disorders and represents a common symptom of rheumatologic diseases, but the data on its prevalence is still limited. Pain is a ubiquitous problem in systemic sclerosis (SSc). SSc-related pain has been studied on the basis of biomedical models and is considered a symptom caused by the disease activity or previous tissue damage. Effective pain management is a primary goal of the treatment strategy, although this symptom in SSc has not yet been investigated in detail. However, these patients do not all respond adequately to pharmacological pain therapies, therefore in these cases a multimodal approach needs to be adopted. This paper must be considered as retracted due to a plagiarism misconduct. See the Retraction note at: https://doi.org/10.4081/reumatismo.2018.1171


Subject(s)
Chronic Pain/etiology , Musculoskeletal Pain/etiology , Scleroderma, Systemic/complications , Analgesics/therapeutic use , Autoantibodies/immunology , Bursitis/etiology , Bursitis/physiopathology , Centromere/immunology , Chronic Pain/epidemiology , Chronic Pain/physiopathology , Chronic Pain/psychology , Chronic Pain/therapy , Cognitive Behavioral Therapy , Combined Modality Therapy , Emotions , Fibromyalgia/etiology , Fibromyalgia/physiopathology , Humans , Models, Biological , Musculoskeletal Pain/epidemiology , Musculoskeletal Pain/physiopathology , Musculoskeletal Pain/psychology , Musculoskeletal Pain/therapy , Pain Management , Prevalence , Scleroderma, Systemic/immunology , Scleroderma, Systemic/physiopathology , Scleroderma, Systemic/psychology , Social Support
8.
Autoimmun Rev ; 12(7): 703-8, 2013 May.
Article in English | MEDLINE | ID: mdl-23207283

ABSTRACT

The introduction of anti-tumour necrosis factor (TNF) agents for the treatment of rheumatoid arthritis (RA), Crohn's disease (CD) or spondyloarthritis (SpA) has revolutionised the therapeutic approach to patients with active disease failing to respond to conventional therapy. However, some of the patients treated with selective TNF inhibitors may develop autoantibodies, such as antinuclear antibodies (ANAs) and anti-double-stranded DNA (anti-dsDNA) antibodies. Furthermore, anti-phospholipid antibodies, which are mainly detected by means of anti-cardiolipin assays, have been found in RA patients receiving TNF blockers. There have also been a number of reports of the development of anti-drug antibodies, of which those against infliximab can interfere with the drug's pharmacokinetics (and therefore its effects), and may also cause acute and delayed infusion and injection site reactions. The onset of autoimmune diseases during biological treatment is rare, but it needs to be promptly recognised in order to plan appropriate patient management. The addition of an immunosuppressive drug can reduce the induction of anti-TNF antibodies.


Subject(s)
Antibodies/therapeutic use , Autoimmunity/drug effects , Tumor Necrosis Factor-alpha/immunology , Antibodies/immunology , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Autoimmune Diseases/drug therapy , Autoimmune Diseases/immunology , Crohn Disease/drug therapy , Crohn Disease/immunology , Humans , Tumor Necrosis Factor-alpha/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL
...